Streetbeat News

VRDN

Viridian Therapeutics, Inc.

https://www.viridiantherapeutics.com

Industry

Biotechnology

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

Open

17.83

Mkt cap

1.4B

Volume

1.5M

High

17.99

P/E Ratio

-4.13

52-wk high

27.20

Low

17.25

Div yield

N/A

52-wk low

11.40

Viridian Therapeutics shares rose following a $225 million public offering and a price target increase by Goldman Sachs from $25 to $31.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 5:43 pm

Goldman Sachs analyst Richard Law has maintained a Buy rating on Viridian Therapeutics and increased the price target from $25 to $31.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:45 pm

Viridian Therapeutics has announced a $225 million upsized public offering, selling 10,666,600 common shares at $18.75 each and 20,000 Series B non-voting convertible preferred shares at $1,250.06250 each. The preferred shares can convert into 1,333,400 common shares. Underwriters have a 30-day option to purchase an additional 1,800,000 common shares.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 6:53 am

Viridian Therapeutics shares are trading higher following an increase in the company's price target from $30 to $38.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 5:17 pm

Needham analyst Serge Belanger has maintained a Buy rating on Viridian Therapeutics and increased the price target from $30 to $38.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 11:06 am

Viridian Therapeutics has announced a proposed underwritten public offering to raise $150 million through the sale of common and preferred stock. This move is likely aimed at raising capital for future growth and development.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 8:01 pm

Viridian Therapeutics (NASDAQ:VRDN) has received varied analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has increased slightly to $34.0. Analysts have maintained or adjusted their ratings and price targets, reflecting their views on the company's market position and financial performance. Despite challenges in revenue growth and profitability, Viridian's debt management is sound.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 8:00 pm

HC Wainwright & Co. has reiterated its Buy rating for Viridian Therapeutics, maintaining a price target of $27. Analyst Douglas Tsao continues to support the stock, indicating confidence in its potential.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 5:43 pm

BTIG analyst Julian Harrison has maintained a Buy rating on Viridian Therapeutics and raised the price target from $46 to $56, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:47 pm

Calavo Growers and several other stocks, including Tesla and Oracle, saw significant gains on Tuesday. Calavo Growers reported better-than-expected earnings and increased its dividend, leading to a 12.5% stock price increase. Mission Produce, Avid Bioservices, and Oracle also posted strong earnings, contributing to their stock price rises.

Portfolio Pulse from Avi Kapoor

September 10, 2024 | 2:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.